Multi-facets of corticotropin-releasing factor in modulating inflammation and angiogenesis

Journal of Neurogastroenterology and Motility

Volumn 21, Issue 1, 2015, Pages 25-32

  Im, Eunok ^a  

^a Pusan National University   (South Korea)

Author keywords

Angiogenesis effect; Corticotropin releasing factor; Inflammation; Urocortins

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; UROCORTIN; UROCORTIN I; UROCORTIN II; UROCORTIN III;

ANGIOGENESIS; ENTERITIS; INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW;

EID: 84920271038     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm14076     Document Type: Review

References (59)

1. Vale W, Spiess J, Rivier C, Rivier J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 1981;213:1394-1397.
2. Vaughan J, Donaldson C, Bittencourt J, et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropinreleasing factor. Nature 1995;378:287-292.
3. Lewis K, Li C, Perrin MH, et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 2001;98:7570-7575.
4. Reyes TM, Lewis K, Perrin MH, et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci USA 2001;98:2843-2838.
5. Hillhouse EW, Grammatopoulos DK. The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 2006;27:260-286.
6. Zmijewski MA, Slominski AT. Emerging role of alternative splicing of CRF1 receptor in CRF signaling. Acta Biochim Pol 2010;57: 1-13.
7. Nishimura E, Billestrup N, Perrin M, Vale W. Identification and characterization of a pituitary corticotropin-releasing factor binding protein by chemical cross-linking. J Biol Chem 1987;262:12893-12896.
8. Chen AM, Perrin MH, Digruccio MR, et al. A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proc Natl Acad Sci USA 2005;102:2620-2625.
9. Muglia L, Jacobson L, Dikkes P, Majzoub JA. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 1995;373:427-432.
10. Vetter DE, Li C, Zhao L, et al. Urocortin-deficient mice show hearing impairment and increased anxiety-like behavior. Nat Genet 2002;31:363-369.
11. Smith GW, Aubry JM, Dellu F, et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20:1093-1102.
12. Bale TL, Contarino A, Smith GW, et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 2000;24:410-414.
13. Im E, Rhee SH, Park YS, Fiocchi C, Taché Y, Pothoulakis C. Corticotropin-releasing hormone family of peptides regulates intestinal angiogenesis. Gastroenterology 2010;138:2457-2467, e1-e5.
14. Anton PM, Gay J, Mykoniatis A, et al. Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation. Proc Natl Acad Sci USA 2004;101:8503-8508.
15. Kokkotou E, Torres D, Moss AC, et al. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol 2006;177:3355-3361.
16. Gay J, Kokkotou E, O'Brien M, Pothoulakis C, Karalis KP. CRH-deficiency is associated with reduced local inflammation in a mouse model of experimental colitis. Endocrinology 2008;149:3403-3409
17. la Fleur SE, Wick EC, Idumalla PS, Grady EF, Bhargava A. Role of peripheral corticotropin-releasing factor and urocortin II in intestinal inflammation and motility in terminal ileum. Proc Natl Acad Sci USA 2005;102:7647-7652.
18. van Tol EA, Petrusz P, Lund PK, Yamauchi M, Sartor RB. Local production of corticotropin releasing hormone is increased in experimental intestinal inflammation in rats. Gut 1996;39:385-392.
19. Wlk M, Wang CC, Venihaki M, et al. Corticotropin-releasing hormone antagonists possess anti-inflammatory effects in the mouse ileum. Gastroenterology 2002;123:505-515.
20. Chang J, Adams MR, Clifton MS, et al. Urocortin 1 modulates immunosignaling in a rat model of colitis via corticotropin-releasing factor receptor 2. Am J Physiol Gastrointest Liver Physiol 2011;300: G884-G894.
21. Kawahito Y, Sano H, Mukai S, et al. Corticotropin releasing hormone in colonic mucosa in patients with ulcerative colitis. Gut 1995; 37:544-551.
22. Wallon C, Persborn M, Jönsson M, et al. Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis. Gastroenterology 2011;140:1597-1607
23. Saruta M, Takahashi K, Suzuki T, Torii A, Kawakami M, Sasano H. Urocortin 1 in colonic mucosa in patients with ulcerative colitis. J Clin Endocrinol Metab 2004;89:5352-5361.
24. Moss AC, Anton P, Savidge T, et al. Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut 2007;56:1210-1217.
25. Yuan PQ, Wu SV, Elliott J, et al. Expression of corticotropin releasing factor receptor type 1 (CRF1) in the human gastrointestinal tract and upregulation in the colonic mucosa in patients with ulcerative colitis. Peptides 2012;38:62-69.
26. Porcher C, Sinniger V, Juhem A, Mouchet P, Bonaz B. Neuronal activity and CRF receptor gene transcription in the brains of rats with colitis. Am J Physiol Gastrointest Liver Physiol 2004;287: G803-G814.
27. Greenwood-Van Meerveld B, Johnson AC, Schulkin J, Myers DA. Long-term expression of corticotropin-releasing factor (CRF) in the paraventricular nucleus of the hypothalamus in response to an acute colonic inflammation. Brain Res 2006;1071:91-96.
28. Million M, Taché Y, Anton P. Susceptibility of Lewis and Fischer rats to stress-induced worsening of TNB-colitis: protective role of brain CRF. Am J Physiol 1999;276(4 Pt 1):G1027-G1036.
29. Clark AR. Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol 2007;275:79-97.
30. Bellavance MA, Rivest S. The HPA-immune axis and the immunomodulatory actions of glucocorticoids in the brain. Front Immunol 2014;5:136.
31. Gué M, Bonbonne C, Fioramonti J, et al. Stress-induced enhancement of colitis in rats: CRF and arginine vasopressin are not involved. Am J Physiol 1997;272(1 Pt 1):G84-G91.
32. Chaniotou Z, Giannogonas P, Theoharis S, et al. Corticotropin-releasing factor regulates TLR4 expression in the colon and protects mice from colitis. Gastroenterology 2010;139:2083-2092.
33. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-241.
34. Singh LK, Boucher W, Pang X, et al. Potent mast cell degranulation and vascular permeability triggered by urocortin through activation of corticotropin-releasing hormone receptors. J Pharmacol Exp Ther 1999;288:1349-1356.
35. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 2006;55:824-832.
36. Mahajan S, Liao M, Barkan P, Takahashi K, Bhargava A. Urocortin 3 expression at baseline and during inflammation in the colon: corticotropin releasing factor receptors cross-talk. Peptides 2014;54:58-66.
37. Chang J, Hoy JJ, Idumalla PS, Clifton MS, Pecoraro NC, Bhargava A. Urocortin 2 expression in the rat gastrointestinal tract under basal conditions and in chemical colitis. Peptides 2007;28:1453-1460.
38. Chatzaki E, Anton PA, Million M, et al. Corticotropin-releasing factor receptor subtype 2 in human colonic mucosa: down-regulation in ulcerative colitis. World J Gastroenterol 2013;19:1416-1423.
39. Theoharides TC, Singh LK, Boucher W, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998;139:403-413.
40. Turnbull AV, Vale W, Rivier C. Urocortin, a corticotropin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats. Eur J Pharmacol 1996;303:213-216.
41. Tsatsanis C, Androulidaki A, Alissafi T, et al. Corticotropin-releasing factor and the urocortins induce the expression of TLR4 in macrophages via activation of the transcription factors PU.1 and AP-1. J Immunol 2006;176:1869-1877.
42. Tsatsanis C, Androulidaki A, Dermitzaki E, Gravanis A, Margioris AN. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2. J Cell Physiol 2007;210:774-783.
43. Wang MJ, Lin SZ, Kuo JS, et al. Urocortin modulates inflammatory response and neurotoxicity induced by microglial activation. J Immunol 2007;179:6204-6214.
44. Torricelli M, Voltolini C, Bloise E, et al. Urocortin increases IL-4 and IL-10 secretion and reverses LPS-induced TNF-alpha release from human trophoblast primary cells. Am J Reprod Immunol 2009;62:224-231.
45. Gonzalez-Rey E, Chorny A, Varela N, O'Valle F, Delgado M. Therapeutic effect of urocortin on collagen-induced arthritis by down-regulation of inflammatory and Th1 responses and induction of regulatory T cells. Arthritis Rheum 2007;56:531-543.
46. Gonzalez-Rey E, Chorny A, Varela N, Robledo G, Delgado M. Urocortin and adrenomedullin prevent lethal endotoxemia by downregulating the inflammatory response. Am J Pathol 2006;168:1921-1930
47. Kubat E, Mahajan S, Liao M, et al. Corticotropin-releasing factor receptor 2 mediates sex-specific cellular stress responses. Mol Med 2013;19:212-222.
48. Bale TL, Giordano FJ, Hickey RP, et al. Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 2002;99:7734-7739.
49. Wakahashi S, Nakabayashi K, Maruo N, Yata A, Ohara N, Maruo T. Effects of corticotropin-releasing hormone and stresscopin on vascular endothelial growth factor mRNA expression in cultured early human extravillous trophoblasts. Endocrine 2008;33:144-151.
50. Bale TL, Giordano FJ, Vale WW. A new role for corticotropinreleasing factor receptor-2: suppression of vascularization. Trends Cardiovasc Med 2003;13:68-71.
51. Tsurumi Y, Murohara T, Krasinski K, et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 1997;3:879-886.
52. Jackson JR, Seed MP, Kircher CH, Willoughby DA, Winkler JD. The codependence of angiogenesis and chronic inflammation. FASEB J 1997;11:457-465.
53. Inada Y, Ikeda K, Tojo K, Sakamoto M, Takada Y, Tajima N. Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation. Peptides 2009;30:365-372.
54. Wang J, Xu Y, Xu Y, et al. Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophinreleasing factor receptor 2. Cancer Invest 2008;26:359-368.
55. Wang J, Jin L, Chen J, Li S. Activation of corticotropin-releasing factor receptor 2 inhibits the growth of human small cell lung carcinoma cells. Cancer Invest 2010;28:146-155.
56. Tezval H, Jurk S, Atschekzei F, et al. Urocortin and corticotropin-releasing factor receptor 2 in human renal cell carcinoma: disruption of an endogenous inhibitor of angiogenesis and proliferation. World J Urol 2009;27:825-830.
57. Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA, Merseburger AS. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways. Prostate 2009;69:443-448.
58. Hao Z, Huang Y, Cleman J, et al. Urocortin2 inhibits tumor growth via effects on vascularization and cell proliferation. Proc Natl Acad Sci USA 2008;105:3939-3944.
59. Arbiser JL, Karalis K, Viswanathan A, et al. Corticotropin-releasing hormone stimulates angiogenesis and epithelial tumor growth in the skin. J Invest Dermatol 1999;113:838-842.